---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031059"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T15:41:10.793725+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity regains Nasdaq minimum bid price compliance after 20-day period

## Summary
- Received Nasdaq notice on Oct 9, 2024 confirming compliance with Listing Rule 5550(a)(2).
- Stock closing bid price was $1.00 or greater for 20 consecutive days from Sept 11 to Oct 9, 2024.
- Non-compliance was first notified on June 18, 2024; this matter is now closed.
- CEO Thomas Jensen stated focus remains on stenoparib Phase 2 trial in advanced ovarian cancer.

## SEC filing metadata
- accession: 0001437749-24-031059
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774924031059/0001437749-24-031059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774924031059/allr20241010_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031059
- JSON: https://secwatch.observer/filing/0001437749-24-031059.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.